Role of Biomarkers in the Integrated Management of Melanoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Jan 10

PMID 35003391

Authors

Piyu Parth Naik

Affiliations

Soon will be listed here.

Abstract

Melanoma, which is an aggressive skin cancer, is currently the fifth and seventh most common cancer in men and women, respectively. The American Cancer Society reported that approximately 106,110 new cases of melanoma were diagnosed in the United States in 2021, with 7,180 people dying from the disease. This information could facilitate the early detection of possible metastatic lesions and the development of novel therapeutic techniques for melanoma. Additionally, early detection of malignant melanoma remains an objective of melanoma research. Recently, melanoma treatment has substantially improved, given the availability of targeted treatments and immunotherapy. These developments have highlighted the significance of identifying biomarkers for prognosis and predicting therapy response. Biomarkers included tissue protein expression, circulating DNA detection, and genetic alterations in cancer cells. Improved diagnostic and prognostic biomarkers are becoming increasingly relevant in melanoma treatment, with the development of newer and more targeted treatments. Here, the author discusses the aspects of biomarkers in the real-time management of patients with melanoma.

Citing Articles

Skin Malignant Melanoma and Matrix Metalloproteinases: Promising Links to Efficient Therapies.

Lazar A, Costea D, Popp C, Mastalier B Int J Mol Sci. 2024; 25(14).

PMID: 39063046 PMC: 11277423. DOI: 10.3390/ijms25147804.

MMP1, MMP9, MMP11 and MMP13 in melanoma and its metastasis - key points in understanding the mechanisms and celerity of tumor dissemination.

Mastalier Manolescu B, Lazar A, Tiplica G, Zurac S, Rebosapca A, Andreescu B Rom J Morphol Embryol. 2024; 65(1):45-52.

PMID: 38527983 PMC: 11146457. DOI: 10.47162/RJME.65.1.06.

Integrative analysis of RNA-sequencing and microarray for the identification of adverse effects of UVB exposure on human skin.

Jang Y, Na H, Shin D, Lee J, Han J, Kim H Front Public Health. 2024; 12:1328089.

PMID: 38444441 PMC: 10913594. DOI: 10.3389/fpubh.2024.1328089.

Insights into Melanoma Clinical Practice: A Perspective for Future Research.

Lam G, Martini C, Brooks T, Prabhakaran S, Hopkins A, Ung B Cancers (Basel). 2023; 15(18).

PMID: 37760601 PMC: 10526186. DOI: 10.3390/cancers15184631.

Mapping knowledge landscapes and emerging trends of the biomarkers in melanoma: a bibliometric analysis from 2004 to 2022.

Wan Y, Shen J, Hong Y, Liu J, Shi T, Cai J Front Oncol. 2023; 13:1181164.

PMID: 37427124 PMC: 10327294. DOI: 10.3389/fonc.2023.1181164.

References

Taylor L, Abraham R, Tahirovic E, van Belle P, Li B, Huang L . High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol. 2017; 30(5):634-639. PMC: 5584688. DOI: 10.1038/modpathol.2016.226. View

Moogk D, Pires da Silva I, Ma M, Friedman E, Vega-Saenz de Miera E, Darvishian F . Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. J Transl Med. 2014; 12:342. PMC: 4272770. DOI: 10.1186/s12967-014-0342-7. View

Gastman B, Zager J, Messina J, Cook R, Covington K, Middlebrook B . Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019; 41(4):871-879. PMC: 6667900. DOI: 10.1002/hed.25473. View

Bolick N, Geller A . Epidemiology of Melanoma. Hematol Oncol Clin North Am. 2021; 35(1):57-72. DOI: 10.1016/j.hoc.2020.08.011. View

Willmes C, Kumar R, Becker J, Fried I, Rachakonda P, Poppe L . SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. Oncotarget. 2016; 7(9):10117-32. PMC: 4891108. DOI: 10.18632/oncotarget.6956. View

Pearl R, Pacifico M, Richman P, Wilson G, Grover R . Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg. 2007; 61(3):265-71. DOI: 10.1016/j.bjps.2007.04.010. View

Kruper L, Spitz F, Czerniecki B, Fraker D, Blackwood-Chirchir A, Ming M . Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006; 107(10):2436-45. DOI: 10.1002/cncr.22295. View

Balch C, Gershenwald J, Soong S, Thompson J, Ding S, Byrd D . Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010; 28(14):2452-9. PMC: 2982783. DOI: 10.1200/JCO.2009.27.1627. View

Rohani M, Parks W . Matrix remodeling by MMPs during wound repair. Matrix Biol. 2015; 44-46:113-21. DOI: 10.1016/j.matbio.2015.03.002. View

10.

Clarke L, Warf M, Flake 2nd D, Hartman A, Tahan S, Shea C . Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol. 2015; 42(4):244-52. PMC: 6681167. DOI: 10.1111/cup.12475. View

11.

Bar-Eli M . Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 2000; 18(3):377-85. DOI: 10.1023/a:1006377309524. View

12.

Pavlova O, Fraitag S, Hohl D . 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma. J Invest Dermatol. 2016; 136(12):2453-2461. DOI: 10.1016/j.jid.2016.07.015. View

13.

Tsoporis J, Mohammadzadeh F, Parker T . S100B: a multifunctional role in cardiovascular pathophysiology. Amino Acids. 2010; 41(4):843-7. DOI: 10.1007/s00726-010-0527-1. View

14.

Shih L, Hsu M, Palazzo J, Herlyn M . The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol. 1997; 151(3):745-51. PMC: 1857834. View

15.

Weinstein D, Leininger J, Hamby C, Safai B . Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol. 2014; 7(6):13-24. PMC: 4086529. View

16.

Nikolin B, Djan I, Trifunovic J, Dugandzija T, Novkovic D, Djan V . MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma. J BUON. 2016; 21(3):691-7. View

17.

Vereecken P, Laporte M, Heenen M . Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review. J Cutan Pathol. 2007; 34(2):139-45. DOI: 10.1111/j.1600-0560.2006.00588.x. View

18.

Yang J, Guo R, Wang H, Ye X, Zhou Z, Dan J . Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs. Cell Rep. 2016; 15(8):1809-21. DOI: 10.1016/j.celrep.2016.04.058. View

19.

Chirivi R, Garofalo A, Crimmin M, Bawden L, Stoppacciaro A, Brown P . Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994; 58(3):460-4. DOI: 10.1002/ijc.2910580326. View

20.

Shinozaki M, Fujimoto A, Morton D, Hoon D . Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004; 10(5):1753-7. DOI: 10.1158/1078-0432.ccr-1169-3. View